Austrian Breast & Colorectal Cancer Study Group
- Country
- 🇦🇹Austria
- Ownership
- Private
- Established
- 1984-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.abcsg.com
Clinical Trials
20
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (19 trials with phase data)• Click on a phase to view related trials
ABCSG 61 / TEODOR : Neoadjuvant TrEatment Optimization Driven by Circulating Tumor DNA and endOcrine Responsiveness
- Conditions
- Early and Locally Advanced Breast Cancer
- First Posted Date
- 2025-07-24
- Last Posted Date
- 2025-08-19
- Lead Sponsor
- Austrian Breast & Colorectal Cancer Study Group
- Target Recruit Count
- 350
- Registration Number
- NCT07084558
- Locations
- 🇦🇹
Landesklinikum Baden BGZ; Abt. f. Allgemein- u. Viszeralchirurgie, Baden, Austria
🇦🇹Dornbirn BGZ; Frauenheilkunde u. Geburtshilfe, Dornbirn, Austria
🇦🇹Landeskrankenhaus Feldkirch Interne E, Feldkirch, Austria
ABCSG C08-Exercise II: Trial of Endurance Exercise Following Adjuvant Chemotherapy for Colorectal Cancer
- Conditions
- Colorectal Carcinoma
- First Posted Date
- 2019-01-30
- Last Posted Date
- 2025-02-19
- Lead Sponsor
- Austrian Breast & Colorectal Cancer Study Group
- Target Recruit Count
- 92
- Registration Number
- NCT03822572
- Locations
- 🇦🇹
Med. Univ. Graz, Graz, Styria, Austria
🇦🇹BKH Kufstein, Kufstein, Tyrol, Austria
🇦🇹KH St. Josef Braunau, Braunau Am Inn, Upper Austria, Austria
A Randomized, Placebo-controlled, Double-blind Phase II Study Evaluating if Glucophage Can Avoid Liver Injury Due to Chemotherapy Associated Steatosis
- Conditions
- SteatohepatitisColorectal Cancer
- Interventions
- Drug: Metformin/Placebo
- First Posted Date
- 2012-02-01
- Last Posted Date
- 2018-12-19
- Lead Sponsor
- Austrian Breast & Colorectal Cancer Study Group
- Target Recruit Count
- 8
- Registration Number
- NCT01523639
- Locations
- 🇦🇹
Medical University Graz, Oncology, Graz, Styria, Austria
🇦🇹Medical University Innsbruck, Internal Medicine, Innsbruck, Tyrol, Austria
🇦🇹Hospital St. Vinzenz, Zams, Tyrol, Austria
Preoperative Combined Induction Chemotherapy With Capecitabine, Oxaliplatin, Bevacizumab and Radiotherapy
- Conditions
- Rectal Cancer
- Interventions
- Drug: preoperative induction chemotherapy in combination with bevacizumab followed by combined radiochemotherapy with capecitabine
- First Posted Date
- 2011-09-14
- Last Posted Date
- 2014-03-07
- Lead Sponsor
- Austrian Breast & Colorectal Cancer Study Group
- Target Recruit Count
- 25
- Registration Number
- NCT01434147
- Locations
- 🇦🇹
Hospital BHB St. Veit/Glan, Surgery, St. Veit a. d. Glan, Carinthia, Austria
🇦🇹Medical University Graz, Oncology, Graz, Styria, Austria
🇦🇹Medical University Innsbruck, Internal Medicine, Innsbruck, Tyrol, Austria
A Phase II Study of Neoadjuvant Trastuzumab+Docetaxel+NPLD+/-Bevacizumab in Her2-pos. Early Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- Drug: Trastuzumab, DocetaxelDrug: Trastuzumab+Docetaxel+NPLDDrug: Trastuzumab+Docetaxel+NPLD+Bevacizumab
- First Posted Date
- 2011-06-06
- Last Posted Date
- 2014-05-13
- Lead Sponsor
- Austrian Breast & Colorectal Cancer Study Group
- Target Recruit Count
- 100
- Registration Number
- NCT01367028
- Locations
- 🇦🇹
Medical University of Graz-Oncology; Coop. Group, Graz, Styria, Austria
🇦🇹State Hospital Leoben, Leoben, Styria, Austria
🇦🇹Gynaegological Medical University Innsbruck, Innsbruck, Tyrol, Austria
- Prev
- 1
- 2
- 3
- 4
- Next